Assuntos
Varizes Esofágicas e Gástricas , Hemorragia Gastrointestinal , Rifaximina , Humanos , Varizes Esofágicas e Gástricas/prevenção & controle , Varizes Esofágicas e Gástricas/etiologia , Fármacos Gastrointestinais/uso terapêutico , Hemorragia Gastrointestinal/prevenção & controle , Cirrose Hepática/complicações , Ensaios Clínicos Controlados Aleatórios como Assunto , Rifaximina/uso terapêutico , Resultado do TratamentoRESUMO
Epilepsy is a chronic brain disease with a global prevalence of 70 million people. According to the World Health Organization, roughly 5 million new cases are diagnosed every year. Anti-seizure drugs are the treatment of choice. However, in roughly one third of the patients, these drugs fail to produce the desired effect. As a result, finding novel treatments for epilepsy becomes inevitable. Recently, angiotensin receptor blockers have been proposed as a treatment to reduce the over-excitation of neurons in epilepsy. For this purpose, we conducted a review using Medline/PubMed and Google Scholar using the relevant search terms and extracted the relevant data in a table. Our review suggests that this novel approach has a very high potential to treat epilepsy, especially in those patients who fail to respond to conventional treatment options. However, more extensive and human-based trials should be conducted to reach a decisive conclusion. Nevertheless, the use of ARBs in patients with epilepsy should be carefully monitored keeping the adverse effects in mind.
